Christoph Lengauer, Ph.D.
Christoph Lengauer joined Third Rock Ventures as a venture partner in 2016 and focuses on the formation of companies discovering and developing novel therapeutics. He brings significant operational and leadership experience to the role.His portfolio company roles include:
- Board member and interim president of Celsius Therapeutics
Christoph is also chief scientific officer and chief drug hunter at Blueprint Medicines. He has a proven record in cancer drug discovery, including contributing to the development of more than 20 drugs that reached first-in-human clinical trials and three FDA-approved medicines. Christoph joined Blueprint Medicines from Sanofi, where he was vice president and global head of oncology drug discovery and preclinical development. Before joining Sanofi, he was executive director and senior unit head of oncology discovery at the Novartis Institutes for Biomedical Research (NIBR). Prior to Novartis, Christoph was an associate professor at the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University School of Medicine. As part of his research, Christoph discovered that all cancers are genetically unstable and was involved in the identification of several cancer driver genes. He has authored more than one hundred scientific articles published in top-tier scientific journals, including Cell, Nature and Science. In 2015, Christoph formed the German Accelerator Life Sciences (GALS) in Boston, which provides high-end consulting to young German biotechs so they can more easily succeed in becoming strong companies and introduce their products to the global market. Christoph studied human genetics in Salzburg, Austria, and received his Ph.D. from the University of Heidelberg in Germany, and his MBA with a focus on medical services management from the Johns Hopkins Carey Business School. Christoph holds adjunct associate professor positions at Johns Hopkins University and Harvard University. He has received numerous awards, including the Boveri Award in Cancer Genetics, the Benjamin Baker Scholar award and a V Foundation scholarship. Christoph was awarded the Novartis Oncology President’s Award for top innovator and has been elected to membership in the Johns Hopkins Society of Scholars.
Back in Austria and Germany, Christoph helped asylum seekers escape deportation. He visited them in detention jails and focused his legal support on Kurds from Iraq, Roma and victims of torture.